Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | CPA1 | P15085 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | NPR3 | P17342 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7273450 | 0.90 | SLC7A5 (0.43) | CTSSCTSKSLC7A5ITGA4ITGB7 | |
| SCHEMBL6548736 | 0.90 | ITGA4 (0.44) | CTSSCTSKSLC7A5ACEITGA4 | |
| SCHEMBL7273304 | 0.86 | ALOX5 (0.36) | CTSSCTSKSLC7A5ITGA4ITGB7 | |
| SCHEMBL9259844 | 0.85 | MAOB (0.39) | CTSSCTSK | |
| SCHEMBL6317701 | 0.84 | CTSS (0.46) | CTSSCTSKGRM2PPARGPPARA | |
| SCHEMBL7248901 | 0.84 | CTSS (0.46) | CTSSCTSKGRM2PPARGPPARA | |
| SCHEMBL1401163 | 0.84 | CTSS (0.46) | CTSSCTSKGRM2PPARGPPARA | |
| SCHEMBL27589932 | 0.83 | CTSS (0.45) | CTSSCTSKGRM2PPARGPPARA | |
| SCHEMBL15577663 | 0.82 | CTSS (0.44) | CTSSCTSKGRM2PPARGPPARA | |
| SCHEMBL30884900 | 0.81 | CTSS (0.43) | CTSSCTSKGRM2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480946-A2 | A HYDROXAMIC ACID THROMBOSPONDIN PEPTIDE ANALOG THAT INHIBITS AGGRECANASE ACTIVITY | MP Biomedicals, L.L.C. (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20030114529-A1 | HO-NH-(C=O)-CH2-CH(-CH2-CH(CH3)2)-(C=O)-V-,V=valine or another amino acid connected with an amino acid sequence of 10 or more amino acids; useful for treating diseases caused by cartilage degradation | MP BIOMEDICALS, LLC | 2003-06-19 | — | — | US | disclosed |
| WO-2003005956-A2 | A HYDROXAMIC ACID THROMBOSPONDIN PEPTIDE ANALOG THAT INHIBITS AGGRECANASE ACTIVITY | ENZYME SYSTEMS PRODUCTS, INC. /(ICN - BIOMEDICALS) (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114529-A1 | HO-NH-(C=O)-CH2-CH(-CH2-CH(CH3)2)-(C=O)-V-,V=valine or another amino acid connected with an amino acid sequence of 10 or more amino acids; useful for treating diseases caused by cartilage degradation | HGFAC, ASPH, SYVN1 | CTSS 422/4885CTSK 491/4885GRM2 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.